{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Levine M"],"funding":["Intramural NIH HHS","Marcus Foundation","National Institutes of Health"],"pagination":["467-469"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9724800"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(4)"],"pubmed_abstract":["Despite historical controversy, pharmacologic ascorbate is emerging as promising cancer therapy via pro-oxidant chemistry. In this issue of Cancer Cell, Schoenfeld et al. describe how intracellular iron pools and reactive oxygen species drive pharmacologic ascorbate's selective toxicity to cancer cells in vitro, in mice, and in humans."],"journal":["Cancer cell"],"pubmed_title":["Data Triumph at C."],"pmcid":["PMC9724800"],"funding_grant_id":["Z01 DK053212","NCT02516670"],"pubmed_authors":["Levine M","Violet PC"],"additional_accession":[]},"is_claimable":false,"name":"Data Triumph at C.","description":"Despite historical controversy, pharmacologic ascorbate is emerging as promising cancer therapy via pro-oxidant chemistry. In this issue of Cancer Cell, Schoenfeld et al. describe how intracellular iron pools and reactive oxygen species drive pharmacologic ascorbate's selective toxicity to cancer cells in vitro, in mice, and in humans.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Apr","modification":"2025-06-01T02:06:43.583Z","creation":"2024-11-14T23:20:36.489Z"},"accession":"S-EPMC9724800","cross_references":{"pubmed":["28399404"],"doi":["10.1016/j.ccell.2017.03.008"]}}